Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cobbe, S.M.
Right arrow Articles by Kastelein, J.J.P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cobbe, S.M.
Right arrow Articles by Kastelein, J.J.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Foreword

S.M. Cobbe1,* and J.J.P. Kastelein2,*

1Department of Medical Cardiology, Glasgow Royal Infirmary, 10, Alexandra Parade, Glasgow G31 2ER, UK
2Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Room F4-159.2,1105 AZ Amsterdam, The Netherlands

* Corresponding authors. E-mail addresses: stuart.cobbe@clinmed.gla.ac.uk and e.vandongen@amc.uva.nl

The first 10% of the full text of this article appears below.

The results of recently reported clinical trials of statin therapy have provided persuasive evidence that low-density lipoprotein (LDL-C) targets and initiation cut-points in lipid-lowering therapy have been set too high in individuals at high or moderately high risk of coronary heart disease (CHD). This evidence has resulted in recommendations for modifications of the National Cholesterol Education Program Adult Treatment Panel III (ATP III) lipid-lowering guidelines.1 The recommendations include an optional LDL-C target of <70 mg/dL (1.8 mmol/L) and an optional treatment initiation cut-point of <100 mg/dL (2.6 mmol/L) in high-risk patients, especially those considered to be at very high risk, and an optional target of <100 mg/dL (2.6 mmol/L) and a treatment initiation cut-point of <130 mg/dL (3.4 mmol/L) in patients at moderately high risk. The . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?